UNSPSC 51272709: Pramocaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C17H27NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88AYB867L5, chemically known as morpholine, 4-(3-(p-butoxyphenoxy)propyl)-, hydrochloride but more generally known as pramocaine hydrochloride, which bears US NIH Compound Identifier 73957. European Medicines Agency schedules Pramocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15004MIG.

Most nations, for tariff and trade purposes, schedule pramocaine hydrochloride under HS 29349990. Pramocaine hydrochloride bears US NLM identifiers UMLS ID C0147008 and NCI Concept Code C47682. SMILES: CCCCOC1CCC(CC1)OCCCN2CCOCC2.CL.

UNSPSC 51272709 Pramocaine hydrochloride is a Commodity code that nominally covers a single topical anesthetic agent, but recent state and local opportunities tagged under this code show little direct procurement of pramocaine itself. Instead, the code appears in solicitations for broader pharmaceutical and medical supply categories: Seminole County, Florida issued an IFB on June 30, 2026 for naloxone and drug deactivation systems; the Texas Health and Human Services Commission posted an RFI on April 3, 2026 regarding direct-to-manufacturer pharmacy benefit programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across multiple participating state and local entities. The issuing bodies span county health departments, state pharmacy and health agencies, and cooperative purchasing consortia serving multiple jurisdictions. The mismatch between the code name (a single pharmaceutical ingredient) and the actual scope of recent solicitations (multi-product pharmaceutical and medical supply procurement) suggests this code does not reliably signal market activity for pramocaine-specific buys.

Activity under this code appears concentrated in the Southeast and Upper Midwest, with recent solicitations from Florida, Texas, Minnesota, and Oregon through MMCAP's multistate vehicle. Seminole County's IFB (Solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, as a fixed-fee contract with a two-year initial term and one-year renewal option. The MMCAP RFP (Solicitation S1070000015802, due March 26, 2026) represents the largest scope among recent opportunities, with manufacturing vendors required to supply generic pharmaceuticals and OTC products through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson) beginning July 1, 2026, evaluated 75 percent on price competitiveness and 25 percent on administrative compliance and EDI capability. Both solicitations require E-Verify compliance and standard commercial insurance coverage; the MMCAP vehicle includes a 3 percent administrative fee. The Texas RFI functions as preliminary market research and does not represent an active procurement opportunity.